Creative Medical Technology Holdings, Inc. Files Amended Annual Report (Form 10-K/A) for Fiscal Year Ended December 31, 2025

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has filed an amended annual report on Form 10-K/A with the Securities and Exchange Commission, covering the fiscal year ended December 31, 2025. This filing contains a comprehensive update on the company’s financial and operational status, corporate governance, executive compensation, ownership structure, and compliance disclosures. Below are the key highlights and potentially price-sensitive information for shareholders and investors.

Key Points & Potential Price-Moving Information

• Company Profile & Security Listing:
  • The company’s common stock is listed on NASDAQ under the trading symbol CELZ.
  • There were 3,696,668 shares of common stock outstanding as of June 30, 2025.
• Filing Status and Compliance:
  • CELZ is classified as a Non-accelerated Filer and is not a well-known seasoned issuer, nor an emerging growth company.
  • The company has filed all reports required by Sections 13 or 15(d) of the Securities Exchange Act of 1934 for the preceding 12 months and has been subject to such filing requirements for the past 90 days.
  • All required Interactive Data Files under Regulation S-T have been filed electronically.
• Internal Controls and Audit:
  • The company’s independent registered public accounting firm did not provide an attestation report on management’s assessment of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
  • No error corrections or restatements that would require recovery of incentive-based compensation for executives were identified in this filing period.
• Executive Compensation & Board Governance:
  • For 2024, the CEO received total compensation of \$560,000 and the CFO received \$300,000.
  • Independent directors receive an annual retainer of \$80,000, plus \$20,000 for each committee they chair. Compensation may be paid in cash and/or stock.
  • An Audit Committee is in place, comprising independent directors, responsible for oversight of financial reporting, internal controls, risk management, and related-party transactions.
• Insider Trading Policy & Corporate Ethics:
  • A new Insider Trading Policy has been adopted and filed as Exhibit 19.1, governing securities transactions by directors, officers, and employees.
  • The company maintains a code of ethics and conduct, available on its website, and commits to disclosing any future amendments or waivers.
• Ownership Structure:
  • As of April 15, 2026, no individual or group is disclosed as owning more than 5% of the company’s common stock.
  • The ownership table includes shares issuable upon exercise of currently exercisable warrants and options.
  • There were no Section 16(a) reporting delinquencies for directors, officers, or >10% owners in the latest fiscal year.
• Market Capitalization & Public Float:
  • The aggregate market value of the company’s common stock held by non-affiliates as of June 30, 2025, was approximately \$4,633,334.
• Related Party Transactions:
  • Details on related party transactions and director independence are disclosed, with the company affirming compliance with NASDAQ and SEC independence requirements for its directors.
• Audit Fees:
  • Audit fees pertain to standard annual financial statement audits and statutory filings, with audit-related fees covering services related to the filing of registration statements on Form S-3.

Analysis & Potential Share Price Impact

• Governance and Compliance: The company’s full compliance with SEC filing requirements and the absence of restatements or material internal control issues is generally positive for shareholder confidence. However, the lack of an auditor attestation on internal controls, while permitted for non-accelerated filers, may be viewed as a risk factor by some institutional investors.
• Executive Compensation: No extraordinary changes or outlier compensation for management were noted, which should be neutral from a governance perspective.
• Insider Trading Policy Adoption: The formal adoption and filing of an insider trading policy enhances transparency and could mitigate regulatory risk, supporting good corporate governance.
• Market Value and Ownership: The small public float and low market capitalization may increase share price volatility and limit institutional interest, but could also make the stock sensitive to news or positive business developments.

Other Significant Disclosures

• No material legal proceedings, bankruptcies, or significant adverse events were disclosed.
• No new share issuances, buybacks, or changes in capital structure were reported.

Conclusion

Creative Medical Technology Holdings, Inc. remains in compliance with all key regulatory requirements. There were no accounting restatements or compliance failures, and the company continues to operate as a non-accelerated filer with a relatively small market capitalization and public float. The adoption of new governance policies and full reporting compliance may improve investor confidence, but the lack of any major business developments or extraordinary events means there is no immediate catalyst for significant share price movement based on this filing alone.

Disclaimer: This article is for informational purposes only and is not investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The above information is based solely on the company’s public SEC filing for the fiscal year ended December 31, 2025.

View CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Historical chart here